Poseida Therapeutics
San Diego, US · Founded 2014 · Delaware corporation · 18,294 employees on LinkedIn · 4 known investors
Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications. The company was acquired by Roche, with its programs now developed by Genentech.
Founders & leadership
Poseida Therapeutics was founded in 2014 by Eric Ostertag.
EO
Eric OstertagFounder
MG
Mark GergenExecutive
Board
AH
Adrian HowdBoard director
DH
David HirschBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$231.8M disclosed across 5 rounds · 2015–2023
▶$25MraisedAug 2023 · 1 investors · BiotechnologyRule 506(b)
▶$25MraisedAug 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Harry J. LeonhardtExecutive Officer
- Mark J. GergenExecutive Officer, Director
- Johanna M. MyletExecutive Officer
- Luke CorningDirector
- Cynthia CollinsDirector
- Marcea B. LloydDirector
- Brent WarnerExecutive Officer
- Charles M. BaumDirector
- Kristin YaremaExecutive Officer
- John SchmidDirector
- Rafael AmadoDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$142.1MraisedApr 2019 · 17 investors · BiotechnologyRule 506(b)
▶$142.1MraisedApr 2019 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SchmidDirector
- Noah BerkowitzDirector
- Marcea Bland LloydDirector
- Eric OstertagExecutive Officer, Director
- David HirschDirector
- Catherine J. MackeyDirector
- Sean MurphyDirector
- Mark GergenExecutive Officer, Director
- Matthew SpearExecutive Officer
- Offering amount
- $150M
- Amount sold
- $142.1M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$30.5MraisedApr 2018 · 7 investors · BiotechnologyRule 506(b)
▶$30.5MraisedApr 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adrian HowdDirector
- Eric OstertagExecutive Officer, Director
- Mark GergenExecutive Officer, Director
- David HirschDirector
- Offering amount
- $30.5M
- Amount sold
- $30.5M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$11.2MraisedAug 2017 · 16 investors · BiotechnologyRule 506(b)
▶$11.2MraisedAug 2017 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adrian HowdDirector
- Eric OstertagExecutive Officer, Director
- Robert LyonsDirector
- Lars EkmanDirector
- Nishan de SilvaExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $11.2M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$23MraisedDec 2015 · 14 investors · BiotechnologyRule 506(b)
▶$23MraisedDec 2015 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric OstertagExecutive Officer, Director
- Nishan de SilvaExecutive Officer, Director
- Lars EkmanDirector
- Offering amount
- $36M
- Amount sold
- $23M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Poseida Therapeutics do?
- Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications. The company was acquired by Roche, with its programs now developed by Genentech.
- Who founded Poseida Therapeutics?
- Poseida Therapeutics was founded by Eric Ostertag in 2014.
- Who are Poseida Therapeutics's investors?
- Poseida Therapeutics's investors include Aisling Capital, Longitude Capital, Rapha Capital Management, LLC, Vivo Capital.
- How much funding has Poseida Therapeutics raised?
- Poseida Therapeutics has disclosed $231.8M raised across 5 rounds.
- Where is Poseida Therapeutics headquartered?
- Poseida Therapeutics is headquartered in San Diego, US.